74 related articles for article (PubMed ID: 7790383)
1. Effects of hypotonic and hypoionic media on drug pumping by P-glycoprotein expressed in epithelial and nonepithelial cell lines.
Ambasch K; Cabantchik ZI; Slotki IN
J Cell Physiol; 1995 Jul; 164(1):117-22. PubMed ID: 7790383
[TBL] [Abstract][Full Text] [Related]
2. Effects of P-glycoprotein expression on cyclic AMP and volume-activated ion fluxes and conductances in HT-29 colon adenocarcinoma cells.
Kunzelmann K; Slotki IN; Klein P; Koslowsky T; Ausiello DA; Greger R; Cabantchik ZI
J Cell Physiol; 1994 Dec; 161(3):393-406. PubMed ID: 7962123
[TBL] [Abstract][Full Text] [Related]
3. Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen.
Lee JS; Paull K; Alvarez M; Hose C; Monks A; Grever M; Fojo AT; Bates SE
Mol Pharmacol; 1994 Oct; 46(4):627-38. PubMed ID: 7969041
[TBL] [Abstract][Full Text] [Related]
4. Membrane potential changes visualized in complete growth media through confocal laser scanning microscopy of bis-oxonol-loaded cells.
Dall'Asta V; Gatti R; Orlandini G; Rossi PA; Rotoli BM; Sala R; Bussolati O; Gazzola GC
Exp Cell Res; 1997 Mar; 231(2):260-8. PubMed ID: 9087166
[TBL] [Abstract][Full Text] [Related]
5. Influence of beta-adrenergic antagonists, H1-receptor blockers, analgesics, diuretics, and quinolone antibiotics on the cellular accumulation of the anticancer drug, daunorubicin: P-glycoprotein modulation.
Ibrahim S; Peggins J; Knapton A; Licht T; Aszalos A
Anticancer Res; 2001; 21(2A):847-56. PubMed ID: 11396174
[TBL] [Abstract][Full Text] [Related]
6. Differential effects of P-glycoprotein inhibitors on NIH3T3 cells transfected with wild-type (G185) or mutant (V185) multidrug transporters.
Cardarelli CO; Aksentijevich I; Pastan I; Gottesman MM
Cancer Res; 1995 Mar; 55(5):1086-91. PubMed ID: 7866993
[TBL] [Abstract][Full Text] [Related]
7. Liposome composition is important for retention of liposomal rhodamine in P-glycoprotein-overexpressing cancer cells.
Kang DI; Kang HK; Gwak HS; Han HK; Lim SJ
Drug Deliv; 2009 Jul; 16(5):261-7. PubMed ID: 19538007
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of P-glycoprotein transport function and reversion of MDR1 multidrug resistance by cnidiadin.
Barthomeuf C; Grassi J; Demeule M; Fournier C; Boivin D; Béliveau R
Cancer Chemother Pharmacol; 2005 Aug; 56(2):173-81. PubMed ID: 15824923
[TBL] [Abstract][Full Text] [Related]
9. DiOC2(3) is not a substrate for multidrug resistance protein (MRP)-mediated drug efflux.
Minderman H; Vanhoefer U; Toth K; Yin MB; Minderman MD; Wrzosek C; Slovak ML; Rustum YM
Cytometry; 1996 Sep; 25(1):14-20. PubMed ID: 8875050
[TBL] [Abstract][Full Text] [Related]
10. Downregulation of JNK/SAPK activity is associated with the cross-resistance to P-glycoprotein-unrelated drugs in multidrug-resistant FM3A/M cells overexpressing P-glycoprotein.
Kang CD; Ahn BK; Jeong CS; Kim KW; Lee HJ; Yoo SD; Chung BS; Kim SH
Exp Cell Res; 2000 Apr; 256(1):300-7. PubMed ID: 10739677
[TBL] [Abstract][Full Text] [Related]
11. Resistance to purine and pyrimidine nucleoside and nucleobase analogs by the human MDR1 transfected murine leukemia cell line L1210/VMDRC.06.
Zeng H; Lin ZP; Sartorelli AC
Biochem Pharmacol; 2004 Sep; 68(5):911-21. PubMed ID: 15294454
[TBL] [Abstract][Full Text] [Related]
12. Role of P-glycoprotein in human natural killer-like cell line-mediated cytotoxicity.
Takahashi M; Misawa Y; Watanabe N; Kawanishi T; Tanaka H; Shigenobu K; Kobayashi Y
Exp Cell Res; 1999 Dec; 253(2):396-402. PubMed ID: 10585262
[TBL] [Abstract][Full Text] [Related]
13. Influence of antipsychotic, antiemetic, and Ca(2+) channel blocker drugs on the cellular accumulation of the anticancer drug daunorubicin: P-glycoprotein modulation.
Ibrahim S; Peggins J; Knapton A; Licht T; Aszalos A
J Pharmacol Exp Ther; 2000 Dec; 295(3):1276-83. PubMed ID: 11082465
[TBL] [Abstract][Full Text] [Related]
14. Multidrug resistance reversal in mouse lymphoma cells by heterocyclic compounds.
Molnár J; Szabo D; Mándi Y; Mucsi I; Fischer J; Varga A; König S; Motohashi N
Anticancer Res; 1998; 18(4C):3033-8. PubMed ID: 9713505
[TBL] [Abstract][Full Text] [Related]
15. Cell-cycle-dependent turnover of P-glycoprotein in multidrug-resistant cells.
Zhang W; Ling V
J Cell Physiol; 2000 Jul; 184(1):17-26. PubMed ID: 10825230
[TBL] [Abstract][Full Text] [Related]
16. Lipid excipients Peceol and Gelucire 44/14 decrease P-glycoprotein mediated efflux of rhodamine 123 partially due to modifying P-glycoprotein protein expression within Caco-2 cells.
Sachs-Barrable K; Thamboo A; Lee SD; Wasan KM
J Pharm Pharm Sci; 2007; 10(3):319-31. PubMed ID: 17727795
[TBL] [Abstract][Full Text] [Related]
17. Kinetics of P-glycoprotein-mediated efflux of paclitaxel.
Jang SH; Wientjes MG; Au JL
J Pharmacol Exp Ther; 2001 Sep; 298(3):1236-42. PubMed ID: 11504826
[TBL] [Abstract][Full Text] [Related]
18. Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin.
Mechetner E; Kyshtoobayeva A; Zonis S; Kim H; Stroup R; Garcia R; Parker RJ; Fruehauf JP
Clin Cancer Res; 1998 Feb; 4(2):389-98. PubMed ID: 9516927
[TBL] [Abstract][Full Text] [Related]
19. Effect of anisotonic conditions on the transport of hydrophilic model compounds across monolayers of human colonic cell lines.
Noach AB; Sakai M; Blom-Roosemalen MC; de Jonge HR; de Boer AG; Breimer DD
J Pharmacol Exp Ther; 1994 Sep; 270(3):1373-80. PubMed ID: 7523659
[TBL] [Abstract][Full Text] [Related]
20. Structural flexibility of the linker region of human P-glycoprotein permits ATP hydrolysis and drug transport.
Hrycyna CA; Airan LE; Germann UA; Ambudkar SV; Pastan I; Gottesman MM
Biochemistry; 1998 Sep; 37(39):13660-73. PubMed ID: 9753453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
